NEW YORK (GenomeWeb) — Interpace Diagnostics announced today that Cigna will now cover its ThyraMir molecular thyroid test.
Interpace's ThyraMir is a microRNA gene expression classifier designed to help diagnose thyroid nodules with indeterminate cytology. In 2017, Cigna began covering the company's ThyGeNext — formerly ThyGenX — next-generation sequencing-based thyroid test.